Gomes Ana R, Zhao Fung, Lam Eric W F
Department of Surgery and Cancer, Imperial College London, London, UK.
Chin J Cancer. 2013 Jul;32(7):365-70. doi: 10.5732/cjc.012.10277. Epub 2013 May 27.
The FOXO3a and FOXM1 forkhead transcription factors are key players in cancer initiation, progression, and drug resistance. Recent research shows that FOXM1 is a direct transcriptional target of FOXO3a, a vital downstream effector of the PI3K-AKT-FOXO signaling cascade. In addition, FOXM1 and FOXO3a also antagonize each other's activity by competitively binding to the same target genes, which are involved in chemotherapeutic drug sensitivity and resistance. Understanding the role and regulation of the FOXO-FOXM1 axis will provide insight into chemotherapeutic drug action and resistance in patients, and help to identify novel therapeutic approaches as well as diagnostic and predictive biomarkers.
FOXO3a和FOXM1叉头转录因子是癌症起始、进展和耐药性中的关键因子。最近的研究表明,FOXM1是FOXO3a的直接转录靶点,而FOXO3a是PI3K-AKT-FOXO信号级联的重要下游效应器。此外,FOXM1和FOXO3a还通过竞争性结合参与化疗药物敏感性和耐药性的相同靶基因来拮抗彼此的活性。了解FOXO-FOXM1轴的作用和调控将有助于深入了解患者的化疗药物作用和耐药性,并有助于识别新的治疗方法以及诊断和预测生物标志物。